Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | AR | P10275 | 12/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29546111 | 0.91 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL12692378 | 0.81 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL17014764 | 0.78 | AR (1.00) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL21823951 | 0.72 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL21823768 | 0.70 | CYP19A1 (0.44) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL21823815 | 0.70 | HPGDS (0.42) | NPC1RAB9AMAPTMAPK1MEN1 | |
| SCHEMBL12692479 | 0.69 | RAB9A (0.79) | NPC1RAB9ASMN1; SMN2MAPTKDM4E | |
| SCHEMBL27413117 | 0.69 | AR (0.69) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL21823777 | 0.69 | KDM4E (0.42) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL21823796 | 0.69 | CYP19A1 (0.45) | NPC1RAB9AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860994-B1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | UNIV BRITISH COLUMBIA (CA) | 2024-08-14 | — | — | EP | disclosed |
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-04-07 | — | — | US | disclosed |
| EP-3860994-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | The University of British Columbia (CA) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020069625-A1 | TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106304-A1 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | BRDT, CBFB, CREBBP | NPC1 4515/4885RAB9A 3925/4885SMN1; SMN2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.